Sheri L. Dodd

Chief Executive Officer (CEO) at TACTILE SYSTEMS TECHNOLOGY

Board

Since July 1, 2024

Age

59 years

Education

Holds a Bachelor of Science degree from the College of Idaho and a Master of Science in Health Planning and Financing from the London School of Economics and London School of Hygiene and Tropical Medicine.

Tenure

Joined the Board of Directors in January 2021 and began serving as Chief Executive Officer on July 1, 2024.

Also at TACTILE SYSTEMS TECHNOLOGY

EMB

Elaine M. Birkemeyer

Chief Financial Officer (CFO)

KTB

Kristie T. Burns

SVP, Marketing & Clinical Affairs

About

Sheri L. Dodd has built an impressive career spanning nearly 30 years in the healthcare industry and now leads as the Chief Executive Officer at TCMD, where her extensive experience in global pharmaceutical, medical device, and digital health sectors fuels her commitment to advancing patient care.

Having held senior roles at esteemed organizations including Medtronic plc, where she managed critical commercial and clinical functions, and Johnson & Johnson, where her work in health economics and reimbursement strategies made a significant impact, she also contributed to global health initiatives during her tenure with the World Health Organization.

At TCMD, her leadership is characterized by a strategic focus on innovation, market expansion, and operational excellence. The transition to the CEO role underscores her dedication to driving sustainable growth and improving access to care, leveraging her deep expertise and robust industry background to steer the company through a dynamic healthcare landscape.

$TCMD Performance Under Sheri L. Dodd

Past Roles

Organization	Role	Date Range	Details
Tactile Systems Technology, Inc.	Board of Directors	Jan 2021 – Jul 2024	Served on the Board prior to becoming CEO
Medtronic plc	President of Medtronic Canada	Mar 2010 – Jun 2024	Responsible for all commercial activities in Canada
Medtronic plc	Vice President and General Manager of Medtronic Care Management Services	Mar 2010 – Jun 2024	Focused on caring for complex patients in the home
Medtronic plc	Vice President and General Manager of Non-intensive Diabetes Therapies	Mar 2010 – Jun 2024	N/A
Medtronic plc	Vice President for Global Health Economics, Reimbursement & Policy, and Global Clinical Research	Mar 2010 – Jun 2024	Oversaw initiatives across the cardiovascular portfolio
Johnson & Johnson	Vice President of Health Economics and Reimbursement for Ethicon, Inc.	Nov 1997 – Mar 2010	Held various roles in the pharmaceutical and medical devices divisions
Orthopedic Surgeons, plc	Outcomes Researcher	Jan 1995 – Nov 1997	N/A
World Health Organization (WHO)	Project Coordinator	May 1988 – Sep 1993	N/A

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Annual Base Salary	$650,000	Annually	Fixed annual pay
Restricted Stock Units	$875,000	Vests in thirds over the first three anniversaries	Granted under the 2016 Equity Incentive Plan

Performance Compensation

Data from FY 2024

Annual Cash Bonus

Metric [Description]	Value/Detail	Additional Details
Target Amount	90% of base salary (approx. $585,000)	Based on an annual base salary of $650,000
Performance Metrics	N/A	Specific performance metrics not provided
Evaluation Period	2024	In line with the management incentive plan
Payment Schedule	Annual	Paid upon meeting undisclosed performance criteria

Performance Stock Units (PSUs)

Metric [Description]	Value/Detail	Additional Details
Target Award Value	$850,000	Total target value of PSUs awarded in 2024
Performance Metrics	Revenue Change (2024), Adjusted EBITDA Margin (2024), Adjusted EBITDA Change (2025)	For 2026, performance goals will be established
Threshold & Cap Range	25% to 175%	Earned based on achievement of performance goals
Vesting Schedule	3 years	PSUs vest over three years
Grant Date	Second business day following Q2 earnings release	Determined based on the earnings announcement schedule
Grant Date Fair Value	$850,000	Reflects the award's fair value at grant date
Grant Date Stock Price	N/A	Specific stock price on the grant date not provided
Settlement	Shares of common stock	PSUs will be settled in shares once earned and vested
Unrecognized Expense	$1.5 million	Total unrecognized pre-tax compensation expense as of June 30, 2024; recognized over a weighted average of 2.2 years